Drug Profile


Alternative Names: Grepafloxacin hydrochloride; Grepax; OPC 17116; Raxar; Vaxar; Vorzan

Latest Information Update: 26 Feb 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Otsuka Pharmaceutical
  • Developer GlaxoSmithKline; Otsuka Pharmaceutical
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Market Withdrawal Acute exacerbations of chronic bronchitis; Bacterial infections; Community-acquired pneumonia; Gonococcal urethritis; Gonorrhoea
  • Discontinued Respiratory tract infections; Sinusitis; Urinary tract infections

Most Recent Events

  • 26 Feb 2008 Discontinued - Clinical-Phase-Unknown for Respiratory tract infections in China (PO)
  • 26 Feb 2008 Discontinued - Clinical-Phase-Unknown for Respiratory tract infections in Taiwan (PO)
  • 26 Feb 2008 Discontinued - Preregistration for Respiratory tract infections in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top